Objective-Clinical studies suggest that platelet P2Y 12 inhibitors reduce mortality from sepsis, although the underlying mechanisms have not been clearly defined in vivo. We hypothesized that P2Y 12 inhibitors may improve survival from sepsis by suppressing systemic inflammation and its prothrombotic effects. We therefore determined whether clopidogrel and the novel, more potent P2Y 12 inhibitor, ticagrelor, modify these responses in an experimental human model. Approach and Results-We randomized 30 healthy volunteers to ticagrelor (n=10), clopidogrel (n=10), or no antiplatelet medication (controls; n=10). We examined the effect of P2Y 12 inhibition on systemic inflammation, which was induced by intravenous injection of Escherichia coli endotoxin. Both P2Y 12 inhibitors significantly reduced platelet-monocyte aggregate formation and peak levels of major proinflammatory cytokines, including tumor necrosis factor α, interleukin-6, and chemokine (C-C motif) ligand 2. In contrast to clopidogrel, ticagrelor also significantly reduced peak levels of IL-8 and growth colony-stimulating factor and increased peak levels of the anti-inflammatory cytokine IL-10. In addition, ticagrelor altered leukocyte trafficking. Both P2Y 12 inhibitors suppressed D-dimer generation and scanning electron microscopy revealed that ticagrelor also suppressed prothrombotic changes in fibrin clot ultrastructure. 
S epsis is one of the most devastating clinical syndromes in medicine, and severe sepsis still has a mortality rate of 20% to 30% and remains resistant to specific pharmacological therapy. 1 Sepsis is characterized by dysregulated systemic inflammatory response to bacterial components, such as endotoxin (lipopolysaccharide [LPS] ). 1 Excessive innate immune activation causes a proinflammatory cytokine storm, extravasation of activated neutrophils, and disturbances of the coagulation system, leading to collateral host tissue damage and increased mortality. 1, 2 Many pathological processes, such as sepsis, involve the formation of platelet-leukocyte aggregates. 3 These platelet-leukocyte interactions have a potentially important role in the pathogenesis of inflammation as they augment leukocyte production of proinflammatory cytokines, leukocyte recruitment, and activation of coagulation. 3, 4 However, the overall magnitude of the contribution of platelets to systemic inflammation and the pathophysiology of human sepsis is not well defined.
Platelet P2Y 12 inhibitors, such as clopidogrel and ticagrelor, inhibit a central ADP-mediated amplification pathway, and therefore, blunt a broad spectrum of platelet functions. 5 It is well established that the antithrombotic effect of this is beneficial for patients with atherothrombosis, which has led to P2Y 12 medications becoming some of the most commonly prescribed medications worldwide. However, in addition, this inhibits the formation of platelet-leukocyte aggregates, which is primarily mediated by inhibition of platelet expression of the adhesion molecule P-selectin. 3 A recent cohort study of 683 421 patients with sepsis has shown that current use of antiplatelet therapy is independently associated with a significant reduction in mortality from sepsis (odds ratio, 0.78; 95% confidence interval, 0.76-0.79; P<0.001). 6 This also corresponds with previous observational studies that suggest that clopidogrel reduces mortality from sepsis. 7, 8 However, the mechanisms underpinning this reduction in mortality have not been clearly demonstrated in vivo because animal models of sepsis conflict about the immunomodulatory effects of clopidogrel, which may be species dependent. [9] [10] [11] [12] Ticagrelor is a novel P2Y 12 inhibitor, which causes more potent and consistent P2Y 12 inhibition than clopidogrel 13 and also weakly inhibits cellular uptake of adenosine. 14 In the PLATelet inhibition and patient Outcomes (PLATO) study of >18 000 patients with acute coronary syndromes, ticagrelor reduced all-cause mortality compared with clopidogrel (hazard ratio, 0.78; P<0.001), which was out of proportion to its incremental cardiovascular benefit. 15 Intriguingly, ticagrelor was associated with lower mortality related to infection (hazard ratio, 0.67; P<0.05) 16, 17 and fewer deaths after sepsis and pulmonary infections than clopidogrel. 18 We therefore sought to determine the mechanistic impact of P2Y 12 inhibitors on pathophysiological processes that are central to sepsis responses in humans. We hypothesized that P2Y 12 inhibitors may reduce mortality from sepsis by suppressing systemic inflammation and its prothrombotic effects, mediated by inhibition of platelet-leukocyte interactions. We hypothesized that the more potent P2Y 12 inhibitor, ticagrelor, suppresses these responses more potently than clopidogrel. To test these hypotheses in humans, we used a well-established model of systemic inflammation, which involves intravenous injection of Escherichia coli endotoxin (LPS) into healthy volunteers. 19 The particular strength of this unique model is that it allows direct assessment of dynamic cellular and molecular pathways that are also major mediators of the pathophysiology of sepsis in humans.
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PLATelet inhibition and patient Outcomes study TNF-α tumor necrosis factor α Figure 1 . Levels of proinflammatory cytokines tumor necrosis factor-α (TNF-α; A), interleukin (IL)-6 (B), chemokine (C-C motif) ligand 2 (CCL2; C), growth colony-stimulating factor (G-CSF; D), IL-8 (E), IL-10 (F), and high-sensitivity C-reactive protein (hsCRP; G) before and after 1 week of antiplatelet treatment and after lipopolysaccharide (LPS) administration (t=0 hours). Data expressed as mean±SEM (n=10 in each group). The overall effect of LPS and the effect of ticagrelor and clopidogrel (both compared with control at each time point) determined using 2-way ANOVA with Dunnett correction for multiple comparisons for the cytokines (*P<0.05, **P<0.01, and ***P<0.001).
For hsCRP, the effect of ticagrelor and clopidogrel compared with control was determined using ANOVA of area under the curve.
Materials and Methods
We randomized 30 healthy volunteers to ticagrelor (n=10), clopidogrel (n=10), or no antiplatelet medication (controls; n=10) to determine their effect on systemic inflammation, which was induced by intravenous injection of E coli endotoxin (2 ng/kg LPS) using a wellestablished method. Additional details on the Materials and Methods are available in the online-only Data Supplement.
Results
Baseline characteristics were comparable in all of the treatment groups ( Figure I ] in the online-only supplement). To avoid any possibility of administering intravenous E coli LPS to a pregnant female, volunteers were only included if they were not of child-bearing potential; no eligible female subjects volunteered and so all recruited volunteers were male.
Compliance was assessed from a diary and pill-count and all subjects were >90% compliant. After LPS administration, all subjects developed anticipated flu-like symptoms and signs of sepsis that peaked at 90 to 180 minutes and resolved within 6 hours (Table II in the online-only Data Supplement). There were no unexpected adverse reactions. Both ticagrelor and clopidogrel reduce peak levels of interleukin (IL)-6, tumor necrosis factor α (TNF-α), and chemokine (C-C motif) ligand 2 (CCL2), whereas ticagrelor additionally reduces peak levels of IL-8 and growth colonystimulating factor and increases peak levels of IL-10.
We assessed systemic inflammation in response to LPS administration by measuring the release of major proinflammatory cytokines, and we determined the modulatory effect of P2Y 12 inhibitors. Plasma levels of IL-6, TNF-α, IL-8, CCL2, growth colony stimulating factor, and high-sensitivity C-reactive protein (hsCRP) significantly increased after LPS administration (all P<0.001; Figure 1 ). Compared with control, both P2Y 12 inhibitors had a marked effect on the proinflammatory cytokine response, reducing peak levels of TNF-α (66% reduction Figure 1C ). In addition, ticagrelor, but not clopidogrel, significantly reduced peak levels of growth colony-stimulating factor (51% reduction; P<0.001; Figure 1D ) and IL-8 (29% reduction; P=0.001; Figure 1E ) compared with control. Ticagrelor, but not clopidogrel, also significantly increased peak levels of the antiinflammatory cytokine IL-10 compared with control (54% increase; P=0.02; Figure 1F ). Neither drug significantly modified the hsCRP response ( Figure 1G ).
Ticagrelor Inhibits LPS-Induced PlateletMonocyte Aggregate Formation
Formation of platelet-leukocyte aggregates (defined as leukocyte expression of the platelet marker CD42a) amplifies leukocyte release of proinflammatory cytokines. 3 We therefore investigated whether this is a mechanism by which P2Y 12 inhibitors reduce systemic inflammation. Ticagrelor significantly reduced formation of platelet-monocyte aggregates compared with control (21% versus 36%; P<0.001) that occurred 6 hours after LPS administration ( Figure 2A ). Clopidogrel also significantly reduced the formation of platelet-monocyte aggregates compared with control (23% versus 36%; P=0.04; Figure 2A ). A similar pattern of effect of LPS and modulation by the antiplatelet medications was seen in Figure 2 . Platelet-monocyte (A) and platelet-neutrophil (B) aggregate formation, and platelet P-selectin expression (C) at baseline, immediately before lipopolysaccharide (LPS) administration and 6 hours after LPS administration, in unstimulated samples and samples stimulated by 30-μmol/L ADP ex vivo. Data expressed as mean±SEM (n=10 in each group). The overall effect of LPS and the effect of ticagrelor and clopidogrel (both compared with control at each time point) were determined using 2-way ANOVA with Dunnett correction for multiple comparisons (*P<0.05, **P<0.01, and ***P<0.001).
platelet-neutrophil aggregate formation, but the effects on platelet-neutrophil aggregate formation were not statistically significant ( Figure 2B ). Platelet P-selectin expression did not significantly change after LPS administration ( Figure 2C ).
Inhibition of platelet P2Y 12 ADP receptors was also assessed by measuring platelet aggregation, platelet-leukocyte aggregate formation and platelet P-selectin expression in response to ADP added ex vivo. Ticagrelor and clopidogrel inhibited ADP-induced platelet aggregation, platelet-monocyte aggregate formation, platelet-neutrophil aggregate formation, and platelet P-selectin expression compared with control at all time points (all P<0.001; Figure 2 ). After randomized treatment, platelet aggregation responses after 5 minutes exposure to ADP (final platelet aggregation response) were 2±1%, 14±6%, and 70±11% in the ticagrelor, clopidogrel, and control groups, respectively (Figure II in the online-only supplement). Final platelet aggregation responses did not significantly change after LPS administration in any of the treatment groups (all P>0.05).
Ticagrelor Increases Neutrophil Counts and Alters Monocyte Dynamics During Systemic Inflammation
Because the formation of platelet-leukocyte aggregates facilitates adhesion of leukocytes to the endothelium and subsequent extravasation, 3 we investigated whether inhibition of these processes by P2Y 12 inhibitors affects leukocyte trafficking. Ticagrelor potentiated the increase in neutrophil count, which was significantly higher than controls 2 to 4 hours after LPS administration (P<0.05; Figure 3B ) and may have been because of inhibition of nonspecific sequestration of neutrophils. Clopidogrel did not have a significant effect ( Figure 3B) . Similarly, subjects receiving ticagrelor showed altered monocyte dynamics. Transient monocyte sequestration was observed after LPS administration in all volunteers, but recovery from this was significantly greater in the ticagrelor and clopidogrel groups ( Figure 3C ). Neither P2Y 12 inhibitor significantly affected the decrease in platelet count that occurred after LPS administration ( Figure 3D ).
LPS Induces Prothrombotic Changes in the Fibrin Network that are Attenuated by Ticagrelor
The development of a stable fibrin clot represents the critical final stage of thrombosis and has the potential to be modified by systemic inflammation. 20 Turbidimetric assays of individual samples showed that fibrin clot maximum absorbance (a measure of clot density) and lysis area (a complex measure that assesses both clot formation and lysis) increased after LPS administration (P<0.001; Figure 4A and 4B). Ticagrelor significantly reduced the rise in maximum absorbance after LPS administration compared with control (percentage increase from baseline of 33% versus 109%; P=0.02; Figure  4A ). Similarly, ticagrelor also reduced the increase in lysis area after LPS administration compared with control (percentage increase from baseline of 46% versus 147%; P=0.02; Figure 4B ). Clopidogrel had a similar, less potent effect that was not statistically significant ( Figure 4A and 4B) .
More detailed analysis of clot ultrastructure using scanning electron microscopy of pooled plasma samples demonstrated that LPS administration resulted in more compact clot formation ( Figure 5 ), shown by a significant increase in fibrin clot density (P=0.02) and a decrease in fibrin fiber diameter (P=0.01; Figures 5 and 6 ). These changes have been shown to increase clot stability and confer resistance to fibrinolysis, both of which contribute to a prothrombotic state. 20 Ticagrelor significantly reduced LPS-induced changes in fiber density and fiber diameter (Figure 6 ), whereas clopidogrel had a similar less potent effect that was not statistically significant. LPS induced a marked increase in D-dimer ( Figure 4C) , which peaked at 4 hours (P<0.001). Ticagrelor significantly reduced peak levels of D-dimer by 48% compared with control (P<0.001) and clopidogrel significantly inhibited peak levels by 19% compared with control (P=0.01).
Discussion
Sepsis is a devastating syndrome for which therapeutic options remain limited. In addition to the immediate collateral host tissue damage and mortality caused by sepsis, there is a 20-fold increase in risk of myocardial infarction and stroke after sepsis by mechanisms that are not fully understood. 21 Data from clinical studies of platelet P2Y 12 inhibitors suggest that their use improves mortality from sepsis. [6] [7] [8] However, animal models of sepsis have conflicted about the immunomodulatory effect of platelet P2Y 12 inhibition on sepsis responses, 9-12 which may be species dependent. We therefore sought to determine the mechanistic impact of P2Y 12 inhibitors on key molecular and cellular pathways that are central to sepsis responses in humans. We investigated the effects of P2Y 12 inhibitors on leukocyte responses, interactions with platelets that may govern such interactions, and with activation of the coagulation system. Our data point to a substantial modulatory effect of ticagrelor in particular and place the regulation of platelet activation at the heart of systemic inflammation induced by LPS in humans.
This study demonstrates marked suppression of response to bacterial endotoxemia by platelet P2Y 12 inhibitors. Both P2Y 12 inhibitors potently reduced peak levels of D-dimer and major proinflammatory cytokines, including IL-6, TNF-α, and CCL2. In contrast to clopidogrel, ticagrelor also significantly reduced peak levels of IL-8 and growth colony-stimulating factor and increased the peak level of IL-10 compared with control. In addition, ticagrelor reduced platelet-leukocyte aggregate formation, altered leukocyte trafficking, and suppressed prothrombotic changes in fibrin clot ultrastructure. Because these changes in fibrin clot structure have been shown to shift the hemostatic balance toward thrombosis, 20 this represents a novel mechanism by which ticagrelor inhibits the prothrombotic consequences of systemic inflammation.
Inhibition of platelet-monocyte aggregate formation demonstrates a mechanism by which platelet P2Y 12 inhibition reduced systemic inflammation because the formation of platelet-monocyte aggregates amplifies monocyte release of proinflammatory cytokines, including TNF-α, CCL2, and IL-8. 22, 23 Levels of residual platelet P2Y 12 reactivity before endotoxin administration significantly correlated with subsequent inflammatory and prothrombotic responses (Appendix in the online-only Data Supplement), suggesting that the responses were P2Y 12 mediated. Ticagrelor and clopidogrel belong to different chemical classes, inhibit platelet P2Y 12 receptors by different mechanisms, and do not have any structural similarities or shared metabolites. From a pharmacological perspective, shared non-P2Y 12 -mediated effects are, therefore, unlikely. P2Y 12 receptors were originally identified to be almost exclusive to platelets, although they have now also been identified on a limited number of other cell types. 24 The extent to which leukocytes express P2Y 12 still remains Figure 4 . Levels of D-dimer (A) and fibrin clot maximum absorbance (B; a measure of clot density) and lysis area under the curve (C; a complex measure that assesses both clot formation and lysis) determined by turbidimetry (expressed as percentage change from baseline value) after treatment and lipopolysaccharide (LPS) administration. Data expressed as mean±SEM (n=10 in each group). The overall effect of LPS and the effect of ticagrelor and clopidogrel (both compared with control at each time point) were determined using 2-way ANOVA with Dunnett correction for multiple comparisons (*P<0.05, **P<0.01, and ***P<0.001).
unclear, particularly as platelets often contaminate isolated leukocyte preparations. In mice, dendritic cells express P2Y 12 , which seems to mediate the secretion of certain cytokines, such as IL-12. 24 This offers an additional mechanism by which P2Y 12 may mediate inflammatory responses, although it has not been established whether dendritic cells function in the same way in humans. Recent studies have demonstrated that vascular smooth muscle cells also express P2Y 12 , which mediates CCL2 release. 25 This may have contributed to the modulatory effect of P2Y 12 inhibition on inflammation, although it has been shown that clopidogrel does not inhibit vascular smooth muscle cells P2Y 12 in rats, possibly because of the potential for nucleated cells to regenerate P2Y 12 .
26 Ticagrelor is also a weak inhibitor of cellular uptake of adenosine, which increases extracellular levels of adenosine.
14 Because adenosine can increase macrophage production of IL-10, which is associated with a reduction in TNF-α and IL-6, this offers a further mechanism by which ticagrelor may modify systemic inflammation. 27 LPS administration induced platelet-leukocyte aggregate formation, which was inhibited by ticagrelor in particular. Platelet-monocyte aggregate formation potentiates monocyte release of proinflammatory cytokines, including TNF-α, CCL2, and IL-8, mediated by nuclear factor-κB. 22, 23 In addition, platelet-neutrophil aggregates have been implicated in the pathophysiology of acute lung injury. 28 Therefore, greater inhibition of the formation of platelet-leukocyte aggregates represents a mechanism by which ticagrelor may have conferred greater protection against excessive innate immune activation during sepsis compared with clopidogrel in the PLATO study. Our data show that LPS administration induced an initial neutropenia and monocytopenia, which is held to be because of rapid sequestration of leukocytes to the endothelium. 29 This was then followed by a rapid increase Figure 5 . Representative electron microscope images of fibrin clots formed from plasma ex vivo in each treatment group immediately before and 6 hours after lipopolysaccharide (LPS) administration. Clots were prepared in duplicate and 4 photographs were taken of each clot at each time point. In the control group, there is an increase in fibrin network density after LPS, whereas in the clopidogrel and ticagrelor groups, this is not apparent.
in neutrophil count because of bone marrow mobilization. It is notable that neutrophil counts were consistently higher in the ticagrelor group compared with the control group, despite lower overall levels of proinflammatory cytokines. This was apparent from early time points onwards, which suggests that this was because of inhibition of leukocyte sequestration, rather than increased bone marrow mobilization, which would tend to have a more delayed effect. It is logical that inhibition of platelet-leukocyte aggregate formation reduces leukocyte sequestration, as formation of platelet-leukocyte aggregates upregulates leukocyte expression of adhesion molecules and facilitates adhesion to the endothelium. 30 In our study, and in other studies, platelet expressed P-selectin was not increased at 30 minutes or 6 hours after LPS administration. This is likely to be because of the transient nature of platelet expression of P-selectin, which is shed by degranulated platelets, although they continue to function normally and aggregate. 31 It has been asserted that the formation of platelet-monocyte aggregates is, therefore, a more reliable marker of platelet activation in vivo. 32 The precise cause of thrombocytopenia related to systemic inflammation has still not been clarified and the relative contribution of platelet activation is unclear. Neither ticagrelor nor clopidogrel significantly attenuated the LPS-induced reduction in platelet count. The findings of our study, therefore, suggest that thrombocytopenia is not entirely mediated by platelet activation or the formation of platelet-monocyte aggregates, as P2Y 12 inhibitors inhibit these processes. The formation of platelet-neutrophil aggregates, or other processes where platelet P2Y 12 has a less prominent role, may therefore have a greater contribution toward thrombocytopenia.
Our study provides many novel insights into potential mechanisms for increased risk of atherothrombotic events after bacteremia and sepsis. 21 Although a prothrombotic state is well recognized in sepsis, 33 the underlying mechanisms are incompletely understood and the relative role of platelets has not been well defined. This study demonstrates that exposure to bacterial LPS directly causes prothrombotic changes in the fibrin network that increase clot stability and confer resistance to fibrinolysis, both of which shift the hemostatic balance toward thrombosis. 20 Platelet P2Y 12 inhibitors inhibited these prothrombotic effects of LPS and our results suggest that this may have been because of a reduction in levels of proinflammatory cytokines because TNF-α, in particular, has been shown to be a potent activator of the coagulation system in vivo. 34 The greater overall effect of ticagrelor on these pathways compared with clopidogrel suggests a mechanism, by which ticagrelor reduced cardiovascular death after infection in the PLATO study. The combined effect of ticagrelor, in particular, on leukocyte production of cytokines, leukocyte sequestration, platelet-leukocyte aggregate formation, and subsequent changes in fibrin clot ultrastructure point to a substantial role for platelets in orchestrating the innate immune response to LPS. This suggests potential for timed platelet P2Y 12 inhibition in patients with infection to modify the risk of sepsis and associated thrombotic complications. In this study and in observational clinical studies, subjects were already taking P2Y 12 inhibitors at the onset of systemic inflammation and sepsis, respectively. However, no studies have established the effect of administration of P2Y 12 inhibitors to patients with established sepsis. The greater infectious and inflammatory burden of established sepsis presents a different balance of risks and benefits and it is critical that any studies that investigate these medications in the context of sepsis carefully address the optimal timing of administration. In sepsis, excess fibrin deposition and impaired anticoagulant mechanisms lead to exhaustion of the coagulation cascade, causing coagulopathy and bleeding. 1 Although antiplatelet medications normally exacerbate bleeding, this may therefore be counterbalanced by attenuating the prothrombotic state that drives the development of coagulopathy during sepsis. In support of this, antiplatelet medications are not associated with excess bleeding in patients with sepsis in observational studies. 7 However, it is important to recognize that patients with established coagulopathy may have their antiplatelet medications discontinued in these studies and are less likely to benefit from these agents.
Ticagrelor and clopidogrel are some of the most commonly prescribed medications worldwide because of their established benefit in the management of atherothrombosis. The results of this study, therefore, have potentially important clinical implications for millions of patients who are currently treated with these medications. In addition, there is great interest in the use of specific immunomodulatory therapy for the Figure 6 . Fibrin fiber diameter (A) and fibrin network density (B; determined by electron microscopy) after lipopolysaccharide (LPS) administration. Data expressed as mean±SEM (n=8 in each group). The overall effect of LPS and the effect of ticagrelor and clopidogrel (both compared with control at each time point) were determined using 2-way ANOVA with Dunnett correction for multiple comparisons (*P<0.05, **P<0.01, and ***P<0.001).
treatment of acute coronary syndromes. 35 The results of our study elucidate the background anti-inflammatory effects of medications that are already used for acute coronary syndromes. This is crucial information for determining the most appropriate inflammatory targets in the design of novel treatment strategies.
A limitation of this study is that clopidogrel has a less potent inhibitory effect in patient populations compared with its effects in healthy volunteers. 36 This is not the case for ticagrelor that has a consistently potent effect in patient populations. 37 Therefore, the results of this study may actually underestimate the additional efficacy of ticagrelor compared with clopidogrel in suppressing systemic inflammation in patients. Although this study demonstrates the key cellular and molecular pathways by which platelet P2Y 12 inhibitors could reduce mortality from sepsis, further randomized human studies are needed to determine whether this improves outcomes in patients.
In conclusion, this study demonstrates that clopidogrel and ticagrelor have a marked effect on multiple critical mechanisms involved in the pathophysiology of sepsis. This suggests a promising line of investigation for novel applications of P2Y 12 inhibitors in a syndrome that has proved elusive to almost all previous pharmacological strategies. The greater overall effect of ticagrelor compared with clopidogrel also provides critical mechanistic insight into the lower mortality after sepsis observed in the ticagrelor group compared with the clopidogrel group in the PLATO study.
